H-CYTE (OTCMKTS:HCYTD) and SANUWAVE Health (OTCMKTS:SNWV) Head to Head Review

Institutional & Insider Ownership

42.5% of SANUWAVE Health shares are held by institutional investors. 14.9% of SANUWAVE Health shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares SANUWAVE Health and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SANUWAVE Health	-1.33%	-23.83%	-20.60%
H-CYTE	-450.40%	N/A	-777.68%

Valuation & Earnings

This table compares SANUWAVE Health and H-CYTE”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SANUWAVE Health	$39.19 million	6.77	-$25.81 million	($8.25)	-3.75
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than SANUWAVE Health.

Risk and Volatility

SANUWAVE Health has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Summary

SANUWAVE Health beats H-CYTE on 7 of the 9 factors compared between the two stocks.

About SANUWAVE Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.